Effect of Bortezomib,Dexamethasone Combined with Lenalidomide in the Treatment of Multiple Myeloma Patients
LIN Yifeng
MA Xiaomei
Abstract：Objective:To investigate the effect of Bortezomib,Dexamethasone combined with Lenalidomide in the treatment of multiple myeloma patients.Method:A total of 96 patients with multiple myeloma who admitted to Longyan First Hospital Affiliated to Fujian Medical University from September 2021 to January 2024 were retrospectively selected as the research objects,they were divided into the control group(Bortezomib and Dexamethasone combined treatment)and the observation group(Lenalidomide combined treatment on the basis of the control group)according to different treatment schemes,with 48 cases in each group.The therapeutic effect,biochemical indexes,immune function and inflammatory response indexes of two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was significant(P<0.05);after treatment,the bone marrow plasma cells proportion,monoclonal protein,β2-microglobulin,CD8+,C-reactive protein,interleukin-6 and tumor necrosis factor-α levels in the observation group were lower than those in the control group,and the levels of CD3+,CD4+and CD4+/CD8+were higher than those in the control group,the differences were significant(P<0.05).Conclusion:The combined use of Bortezomib,Dexamethasone and Lenalidomide in patients with multiple myeloma can improve the clinical treatment effect,regulate immune function,and reduce biochemical indicators and inflammatory response indicators.
Keywords：BortezomibDexamethasoneLenalidomideMultiple myelomaBiochemical indexImmune functionInflammatory response
Publication Date：2025-04-05
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 24-27 )